Findings can lead to gut replacement therapy in people with intestinal deficiencies
Working with gut stem cells from humans and mice, scientists from the Johns Hopkins Children’s Center and the University of Pittsburgh have successfully grown healthy intestine atop a 3-D scaffold made of a substance used in surgical sutures.
In a further step that takes their work well beyond proof of concept, researchers report their laboratory-created intestine successfully regenerated gut tissue in the colons of dogs with missing gut lining.
The experiments, described ahead of print in the journal Regenerative Medicine, bring researchers closer to creating an implantable intestine as replacement therapy for a range of devastating disorders – including infections, cancer and trauma – that result in loss or death of gut tissue. Chief among them is a condition that affects 12 percent of premature newborns, called necrotizing enterocolitis (NEC), which is marked by the rapid death of intestinal cells and permanent loss of intestinal tissue.
The tube-shaped scaffold, designed several years ago in collaboration with Cornell University researchers and composed of biodegradable material similar to that used in surgical sutures, was a big first step on the quest to develop an implantable replacement intestine. But the new work pushes that effort further because it shows how stem cells, when mixed with immune and connective tissue cells, can grow into normal gut tissue around the scaffold and function inside a living mammal.
Researchers caution that a fully functioning replacement intestine for humans is far off, but they say their results have laid the critical groundwork to do so.
“Our experiments show that the architecture and function of our lab-made intestine strikingly resemble those of the healthy human gut, giving us real hope that our model could be used as the backbone for replacement intestine,” says principal investigator David Hackam, M.D., Ph.D., the Johns Hopkins Children’s Center’s surgeon-in-chief, who initiated and conducted most of the work at the University of Pittsburgh.
In an initial set of experiments reminiscent of a peanut butter-and-jelly sandwich technique, researchers took stem cells from the colons of babies undergoing intestinal surgeries and from mice, then added immune cells called macrophages, the body’s scavengers that seek out and engulf debris along with foreign and diseased cells. To this mix, they added cells called fibroblasts, whose function is to form collagen and other connective substances that bind tissues and organs together. The idea, the scientists say, was to create a mixture that closely mimics the natural composition of the gut.
“Intestinal cells do not grow and develop in a vacuum, so we sought to recreate the richness of the human gut, Hackam says. “We took the PB & J approach, adding a layer of stem cells on top of the scaffold, then topping them with a mixture of immune and collagen cells.”
Adding these components, they report, enhanced the growth of intestinal stem cells and differentiation into various mature cell types critical to the function of a healthy intestine. In comparison, stem cells grown in isolation without immune and connective cells in the mix grew more slowly and failed to differentiate well into multiple cell types.
In another set of experiments, researchers added probiotic bacteria to the newly created intestinal tissue. Doing so further amplified the growth and differentiation of new gut cells, specifically the growth of Paneth cells responsible for production of infection-fighting proteins that guard against intestinal infections, Hackam says, a finding that highlights the therapeutic potential of certain probiotics for NEC. Next, the team added bacteria-laden stool cells obtained from infants with NEC, but they observed a dramatic decrease in the number of intestinal cells called goblet cells, which are responsible for the production of protective mucus that coats and shields the intestine – a common occurrence in NEC. The observation, Hackam says, supports the notion that certain gut bacteria present in the colons of babies with NEC are responsible for sparking the rapid death of gut tissue that occurs in the condition.
Next, researchers implanted the newly created intestine into the bellies of mice. In a matter of days, the implanted intestine began producing new intestinal stem cells and stimulated the growth of new blood vessels around the implant. That observation, researchers say, affirmed the ability of the 3-D intestine to spur the growth of new tissue not only in lab dishes, but also in living organisms.
In a final step, the investigators implanted pieces of the newly created intestine – about 1.6 inches in length – into the lower portion of dog colons lacking parts of their intestinal lining. For two months, the dogs underwent periodic colonoscopies and intestinal biopsies. Strikingly, the guts of dogs with implanted intestines healed completely within eight weeks. By contrast, dogs that didn’t get intestinal implants experienced continued inflammation and scarring of their guts.
The Latest on: Regenerative medicine
via Google News
The Latest on: Regenerative medicine
- BRIEF-China Regenerative Medicine International Proposes To Raise Between About Hk$351.72 Mln & Hk$354.23 Mlnon November 28, 2019 at 4:02 pm
Nov 28 (Reuters) - China Regenerative Medicine International Ltd: * PROPOSES TO RAISE NOT LESS THAN HK$351.72 MILLION & NOT MORE THAN ABOUT HK$354.23 MILLION BY ISSUING OFFER SHARES * TO ISSUE BETWEEN ...
- Regenerative Medicine Market: Facts, Figures and Analytical Insights 2019-2024on November 28, 2019 at 1:48 am
Nov 28, 2019 (AmericaNewsHour) -- As stated by the research report published by Azoth Analytics in August 2019, the Global Regenerative Medicine Market was valued at USD 22,814.45 million the year ...
- Hitachi develops automation technology of 3D culture to expand regenerative medicine businesson November 27, 2019 at 9:29 pm
Furthermore the support service to establish an automatic manufacturing process for customers who are considering automation of manufacturing regenerative medicine products will be started on December ...
- Global Regenerative Medicine Market Analysis 2018-2019 with Forecasts to 2025 - ResearchAndMarkets.comon November 27, 2019 at 4:30 pm
The "Regenerative Medicine Market Size, Outlook and Growth Opportunities, 2019- 2025" report has been added to ResearchAndMarkets.com's offering. This report includes the latest predictions of the ...
- Hitachi Developed Automation Technology of 3D Culture to Expand Regenerative Medicine Businesson November 26, 2019 at 8:17 pm
A schematic diagram of automated new 3D culture*10 Furthermore the support service to establish an automatic manufacturing process for customers who are considering automation of manufacturing ...
- Regenerative Medicine Firm Advances Multifaceted Pipelineon November 26, 2019 at 5:11 pm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) announced in a news release the status of its various programs. Regarding its RCI-02 dermal injector, the biotech received the functional prototype ...
- Regenerative Medicine Market Trends, Drivers, Strategies, Size, Demand, Growth, Applications and Competitive Landscape 2024on November 26, 2019 at 12:36 am
Nov 26, 2019 (The Expresswire) -- Regenerative Medicine Market 2019 Global Industry research report offers you market size, industry growth, share, development trends, product demand, investment plans ...
- AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz ...on November 24, 2019 at 2:45 pm
AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the ...
- Heartseed Raises $26M in Series B Funding to Accelerate Development of iPSC-derived Regenerative Medicine for Heart Failureon November 22, 2019 at 4:00 am
which has supported Heartseed from Series A. “I have been involved in the research of cardiac regenerative medicine for the past 20-years as a pioneer in this field and solved all the major challenges ...
- MEDIA ADVISORY: Advances in Regenerative Medicine through Exosome Therapy presented by Dr. Ducan Ross, founder of Kimera Labs at Perpetual Lifeon November 21, 2019 at 5:43 am
As a pioneer in the development of cell-free exosome products, Dr. Ross's research has been and continues to be employed by many physicians and clinics in a variety of regenerative medicine protocols.
via Bing News